Evommune financials
$8.35−0.48%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 |
|---|---|
| Revenue | $13.0M |
| Gross profit | $13.0M |
| Gross margin | 100.0% |
| Operating income | -$81.1M |
| Net income | -$68.9M |
| Net margin | −529.8% |
| Diluted EPS | $-11.22 |
| EBITDA | -$79.7M |
| Operating cash flow | -$76.4M |
| Free cash flow | -$76.7M |
| Diluted shares | 6.1M |
Balance sheet
| Period end | Dec 31 |
|---|---|
| Cash & equivalents | $44.1M |
| Short-term investments | $105.1M |
| Total debt | $181.0K |
| Total assets | $224.9M |
| Total liabilities | $19.4M |
| Shareholders' equity | $205.6M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology